CASI Pharmaceuticals Inc（CASI）股票分析CASICASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CASI Pharmaceuticals Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant challenges, including delisting from Nasdaq, a massive price drop, poor financial performance, and no positive trading signals. The lack of positive catalysts and the transition to OTC markets further increase the risk, making it unsuitable for the given investor profile.

2 analysts cover CASI: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.00.